Company: WELNF
Filing Date: 2025-11-12
Form Type: DEFM14A
Source: 0001104659-25-109577
Chunk: 159

Company: Integrated Wellness Acquisition Corp
Filing Date: 2025-11-12
Form: DEFM14A
Chunk 159
---
 conversion price of One Dollar ($1.00), rounded up to the nearest whole number of ordinary shares. Additionally, pursuant to the Third Extension Note, as amended, the remaining up to $2.5 million, if advanced for purposes of extending period in which IWAC may complete its initial business combination, may be converted pursuant to the same formula.

The exercise of IWAC’s directors’ and executive officers’ discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of interest when determining whether changes to the terms of the Business Combination or waivers of conditions are appropriate and in IWAC’s shareholders’ best interest.

In the period leading up to the closing of the Business Combination, events may occur that, pursuant to the Business Combination Agreement, may require IWAC to agree to amend the Business Combination Agreement, to consent to certain actions taken by Btab or to waive rights that IWAC is entitled to under the Business Combination Agreement. Such events could arise because of changes in the course of Btab’s business, a request by Btab to undertake actions that would otherwise be prohibited by the terms of the Business Combination Agreement or the occurrence of other events that would have a material adverse effect on Btab’s business and would entitle IWAC to terminate the Business Combination Agreement. In any of such circumstances, it would be at IWAC’s discretion, acting through its board of directors, to grant its consent or waive those rights. The existence of financial and personal interests of one or more of the directors

<div align='center'>60</div>

TABLE OF CONTENTS

described in the preceding risk factors may result in a conflict of interest on the part of such director(s) between what he or they may believe is best for IWAC and its shareholders and what he or they may believe is best for himself or themselves in determining whether or not to take the requested action. As of the date of this joint proxy statement/information statement/prospectus, IWAC does not believe there will be any changes or waivers that IWAC’s directors and executive officers would be likely to make after shareholder approval of the Business Combination Proposal has been obtained. While certain changes could be made without further shareholder approval, IWAC will circulate a new or amended joint proxy statement/ information statement/prospectus and resolicit IWAC’s shareholders if changes to the terms of the transaction that would have a material impact on its shareholders are required prior to the vote on the Business Combination Proposal.

Some of the Btab and IWAC officers and directors may